Skip to : [Content] [Navigation]
 

Biomaterials Talk

 
 
Nov
30

As Reported in Innovations-Report.com:

Researchers from the Universidad Rey Juan Carlos have developed biocompatible polymeric materials derived from lactic acid.

These materials could be used in the architecture of cardiac tissue, as support for drugs, and biodegradable fixation devices for the repair of small broken bones such as the ones in the hands, joints and feet.

These orthopedic implants are gradually metabolized and naturally assimilated by the body. Their mass is progressively transferred into the broken bone, helping the healing process and thereby eliminating the need for a second intervention.

These new materials are obtained through molecular catalysis, and require breaking the cyclic dimer of lactic acid “lactide” to obtain polylactic acid (PLA). The lactide is a renewable natural resource that occurs as a by-product of the fermentation of biomass with high starch content, such as maize, wheat, or sugar beet. As in every polymerization process, a catalyst is required and in this case the active compound must be a metal.

Consequently, this catalytic process has been studied with different metals such as tin, yttrium, titanium, aluminum and other lanthanides. However, since on some occasions residues of the catalyst can be incorporated into the polymer, it is important to preserve the biocompatibility and zero toxicity of the PLA by insuring that the metallic catalyst used is biologically benign and does not have a negative impact on tissue. These medical uses have favored the use of metals like magnesium, calcium or zinc, all of them common inside the human body.

On a different front, PLAs are being investigated as a possible raw material of many manufactured products, since they present similar and in some cases better properties than traditional polymers that are derived from the bioresistant poly (a-olefin), with the significant added benefit of biodegradation.

While their production costs were considered too high in the past, recent developments in the treatment and production combined with the contrasting ecological hazard represented by petroleum derived polymers have brought these types of biodegradable polymers to very competitive positions.

One of the most recent and relevant examples that confirm this growing expansion, is the joint endeavor by Cargill. Inc., and The Dow Chemical Co., who have recently announced the mass production of many tons of PLAs.

The scientific community shows a growing interest to find catalysts that are capable of producing such biomaterials with well defined microstructures, since this defines the mechanical properties, the biodegradability, and the overall usability of the material.

With this in mind, the research group from the URJC, formed by Dr Andrés Garcés and Carlos Alonso and coordinated by Dr Luis Fernando Sánchez-Barba, is working in collaboration with the UCLM to develop different families of catalysts based on magnesium and zinc and stabilized by ligands like heteroscorpionate of they type “NNN”, capable of polymerizing the ε-caprolactone and the lactide in a controlled manner. These are extremely active initiators with a chemical formula of [M(R)(NNN)] (M = Mg, Zn) that achieve a productivity of 21.000 Kg of poly-ε- caprolactone (PLC) produced per mol of Mg each hour at room temperature.

Moreover, some of these initiators allow for a controlled growth of the PLA’s microstructure. This is linked to the influence that the heteroscorpionate exerts during the process of opening the cyclic dimmer, which in turn grants control over the future specifications and applications of the produced material such as a high molecular mass, crystallinity as well as high fusion temperature (165ºC), all of it generating a great interest from industry.

This study has been published in the latest editions of the Inorganic Chemistry & Organometallics magazine.

Nov
26

A recent article brought up a very interesting question: How does culture or religion affect the acceptance of biomaterials? The term halal refers to substances that are permissible within Islamic law (akin to the word kosher in Judaism).

A research center in Pakistan is beginning a program dedicated to biomaterials development. One of the goals of the program is to find materials that are halal. Of course, that is not the program’s only purpose. The COMSATS Institute of Information Technology Lahore is intended to drive the country’s focus to develop implants for national needs. It will include undergraduate and graduate level classes, scheduled to start in early 2008.

Nov
21

The Minister for Enterprise, Trade and Employment, Micheál Martin TD, has announced Science Foundation Ireland (SFI) research investment awards amounting to €87 million across a number of industry-academic projects.

Among the projects is the Network of Excellence for Functional Biomaterials (NFB), which was awarded just over €4.3 million (about $6.4 million) from SFI with an additional €1.7 million to be provided by industrial partners.

NFB will develop new technologies to carry therapeutic genes and other agents to specific target sites. These will include coatings for medical devices, tissue repair scaffolds and also programmable nanospheres, which carry a therapeutic agent to a specific location via the bloodstream.

Nov
13

So yesterday I talked about how innovative polymers are making a comeback in the device world. What I didn’t mention was the legislation that may or may not be responsible for the survival of the sector.

The C&EN article gave significant credit to the Biomaterials Access Assurance Act for the success of companies in the biomaterials industry. Indeed, Bob Ward of PTG specifically mentions the Act as providing protection for his firm.

The Biomaterials Access Assurance Act of 1998 was considered a legislative success. In essence it provides suppliers with protection from lawsuits when the materials they supply are used in implanted medical devices manufactured and sold by others.

But the question remains: How effective has this legislation been in encouraging companies to provide materials for medical use? If anyone has an answer, I’d sincerely like to know. This could even be the topic of an article in MD&DI.

Nov
12

In one of my very first posts on this blog I lamented the decline of development of innovative biomaterials for use in devices. Not an auspicious beginning, I’ll admit. My blog, dedicated to what some thought a sluggish part of the industry, seemed perhaps outdated, even misguided.

But it turns out I am far more hip than I realized. Like wide-leg pants, biomaterials have come back into fashion. And I couldn’t be happier to have been wrong.

My evidence? An article that appears in the November 5 issue of Chemical and Engineering News. The American Chemical Society discusses the recent resurgence innovative for use in medical devices. The author talks about Solvay’s new polymers, DSM’s polyethylene for medical sutures, the BioMedical Materials (BMM) program, $125 million program to investigate new materials to improve health care. BMM’s participants include Medtronic, DSM, and Philips Medical.

In addition, that article talks about how when large companies (like Dow Corning) left the industry, it opened the door for smaller suppliers. Bob Ward (Polymer Technologies Group) says in the 15 years or so since the big guys left the business, the value of plastics used in medical devices has increased 10 times, while the value of plastics for all other uses has only doubled.

Take that, skinny-legged jeans!

Nov
7

SyntheMed Inc. , a biomaterials company engaged in the development and commercialization of anti-adhesion, tissue repair, and drug delivery products, announced today that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow SyntheMed to sell, from time to time, up to $20 million of its common stock, debt securities, preferred stock, warrants to purchase common stock, preferred stock or debt securities, or any combination thereof in one or more offerings. The terms of any offering under the registration statement will be established at the time of the offering and will be described in a prospectus supplement that SyntheMed will file with the SEC. SyntheMed expects to use the net proceeds from any sale of securities under this registration statement for general corporate purposes including expenses associated with the anticipated US-market launch of REPEL-CV(R) Adhesion Barrier, research and development expenses for new product opportunities including potential applications of its polymer film technology in spine and ENT surgery, and costs related to post-approval clinical trials for REPEL-CV.

For the full release click here.

Nov
6

Nontoxic nanomaterials may soon replace fluorescent and radioactive labeling used for probing biomolecules and cells. Researchers hope to harness semiconductor nanocrystals because these possess a broad excitation spectrum (they illuminate with varying stimuli), a narrow emission spectrum (they don’t wash out or transfer to surrounding cells); a tunable emmision peak (the brightness can be adjusted); and a long fluorescent life.

However, the band gap of most emissive semiconductors, with the exception of cadmium-containing materials, is either too high or too low to easily make visible emitting quantum dots. And cadmium is toxic and therefore unsuitable for medical applications. To counter this problem, researchers have turned to doped nanocrystal systems. Doping is the process of intentionally introducing impurities into an extremely pure (or intrinsic) semiconductor in order to change its electrical properties. Recently, the researchers created a synthesis of nanoscopic materials comprising zinc, selenium, sulfur, and manganese. The combination can be used for pH sensing, although such a system requires equipment beyond the capability of commercial microscopes.

Despite these challenges, the researchers remain confident about future applications in the medical device field.

Nov
6

On 14 November, the Nanotechnology and Healthcare Products Webcast will provide an overview of nanotechnology within the healthcare industry, discuss this emerging state of the science, evaluate global policy and governance issues, and explore practical risk management strategies.
Click here for more information.